Previous 10 | Next 10 |
A stock that trades at $15 or less isn't necessarily a bargain. Often, a stock trading that low is risky and anything but a bargain. However, biotech stocks Novavax (NASDAQ: NVAX) , MannKind (NASDAQ: MNKD) , and Anavex Life Sciences (NASDAQ: AVXL) all trade at $15 or l...
Summary Anavex 2-73/blarcamesine at high concentrations in early Alzheimer's disease leads to improvements in cognition and activities of daily living that are largely sustained for 148 weeks in most individuals. Alzheon's ALZ-801 reduces cognitive decline in ApoE4 carriers by about the...
Summary Anavex Life Sciences Corp. presented solid-looking Alzheimer's data last month. Critics found a number of anomalies, some more real than others. Anavex Life Sciences management hasn't yet presented responses to these questions. Although the company posted ...
Summary Lecanemab only significantly slows down the progression of Alzheimer's disease in APOE4 carriers. Lecanemab is suspected of causing at least three deaths. The FDA may still grant approval to lecanemab with a warning label regarding brain bleeds and brain swelling. Medica...
Summary A new as-yet-unreported death among those taking Biogen's Lecanemab in an extended post-Phase 3 study has emerged. Biogen's Lecanemab has a PDUFA date of January 6, 2023; the FDA will announce its preliminary (or final) approval or rejection. Six days later, Anavex Life Scie...
Can a biotech stock that's down by about 40% in the last month have any chance of rallying to multiply in value by a factor of five over the next two years? Prospective investors looking for a big catch may be tempted to look to Anavex Life Sciences , (NASDAQ: AVXL) a clinical-stage drug ...
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...
As a pre-revenue biotech company that's approaching decisive clinical and regulatory milestones, Anavex Life Sciences (NASDAQ: AVXL) isn't an investment for the faint of heart. It has no products on the market, and its share price is, for now, entirely dependent on how much the results of...
NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...
Summary On December 1, 2022 Anavex presented data from its Phase II/III Alzheimer's study claiming it met its primary and secondary endpoints. The way the endpoints were discussed led to confusion regarding which were the primary endpoints. Of the endpoints presented, there are nume...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...